News | September 11, 2007

Bioresorbable Collagen Matrix May be Used to Deliver Drugs

September 12, 2007 – Innocoll Technologies Ltd. has entered into a strategic collaboration with TGR BioSciences Pty Ltd. to evaluate the combination of Innocoll's collagen-based drug delivery technology, CollaRx, with TGR Biosciences’ proprietary wound healing compound, TGR-265.
Innocoll's CollaRx technology platform is a biocompatible and fully bioresorbable collagen matrix for localized drug delivery. It is comprised of purified type I fibrillar collagen and can be prepared in the form of a freeze-dried sponge or film-cast membrane using a proprietary manufacturing process. Both CollaRx formats can be surgically implanted or applied topically to wounds, enabling drugs to be delivered locally to the intended site of action and thereby minimize any systemic-related side effects.
CollaRx matrices are biodegraded by natural enzymatic activity and fully resorbed within a few days or up to several weeks according to the local physiological environment. The in vivo release of drug from the CollaRx matrix takes place via a combination of diffusion and natural breakdown of the collagen to provide both rapid and prolonged release, which can be controlled through formulation techniques and processing variables. The CollaRx matrix also provides an initial scaffold for cell migration and proliferation, thereby stimulating production of certain cytokines and growth factors and so itself plays an integral role in the repair and replacement of both hard and soft tissue by accelerating tissue granulation and epithelialization.
TGR-265 is a naturally-derived bioactive protein that has been shown through extensive in vitro and in vivo pre-clinical testing to stimulate the fibrogenic response, production of host type 1 collagen and deposition of extracellular matrix.
Under the terms of the collaboration, Innocoll will incorporate TGR-265 into the CollaRx sponge and membrane formats for further evaluation. TGR BioSciences will fund development of the formulated products.
“This strategic collaboration is indicative of Innocoll’s intention to fully exploit its technology platforms through partnership with innovative biotechnology and pharmaceutical companies looking to deliver their drugs locally,” said Dr. Michael Myers, president and CEO of Innocoll. “Despite investing heavily in the late stage clinical development of our own internal pipeline of products, we believe that partnerships such as this with TGR BioSciences are important for providing the company with a wide and diversified portfolio of development projects for long term, sustainable growth.”

For more information: www.innocoll.com, www.tgr-biosciences.com

Related Content

News | October 01, 2008
October 2, 2008 - Canica Design Inc., said its new SutureSafe is now available.
News | July 17, 2008
July 18, 2008 – 3M Health Care and Greystone Pharmaceuticals Inc.
News | June 11, 2008
June 12, 2008 – Nevada Cancer Institute’s (NVCI) Diagnostic Imaging Department said it has been approved to participa
Technology | May 15, 2008
Results of an independent clinical study conducted by U.S.
News | May 14, 2008
May 15, 2008 - Apria Healthcare Group Inc.
News | May 04, 2008
May 5, 2008 – ConvaTec said its Flexi-Seal Fecal Management System (FMS), a temporary containment device indicated fo
News | May 01, 2008
May 2, 2008 - Results of an independent clinical study conducted by U.S.
News | April 30, 2008
May 1, 2008 – Covidien today introduced the VascuSeal Vascular Sealant System throughout Europe and in select Middle
News | April 27, 2008
April 28, 2008 - Derma Sciences said today the FDA has given clearance to another dressing in the MEDIHONEY product l
Overlay Init